InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
TRUSTUNITS1000000 Free
03/17/24 12:41 PM
profile icon
TRUSTUNITS1000000 Free
03/17/24 12:41 PM
profile icon
TRUSTUNITS1000000 Free
03/17/24 12:40 PM
profile icon
TRUSTUNITS1000000 Free
03/12/24 11:35 AM
profile icon
TRUSTUNITS1000000 Free
02/11/24 11:06 AM
profile icon
TRUSTUNITS1000000 Free
01/04/24 10:55 PM
profile icon
TRUSTUNITS1000000 Free
01/04/24 10:54 PM
profile icon
TRUSTUNITS1000000 Free
01/03/24 11:41 AM
profile icon
TRUSTUNITS1000000 Free
01/03/24 11:40 AM
profile icon
TRUSTUNITS1000000 Free
01/03/24 11:39 AM
profile icon
TRUSTUNITS1000000 Free
01/03/24 11:39 AM
profile icon
TRUSTUNITS1000000 Free
12/14/23 10:48 AM
profile icon
TRUSTUNITS1000000 Free
12/09/23 10:28 AM
profile icon
TRUSTUNITS1000000 Free
12/09/23 10:27 AM
profile icon
TRUSTUNITS1000000 Free
12/09/23 10:27 AM
profile icon
TRUSTUNITS1000000 Free
12/09/23 10:26 AM
profile icon
TRUSTUNITS1000000 Free
12/05/23 10:37 AM
profile icon
TRUSTUNITS1000000 Free
11/16/23 10:06 AM

Novelion Therapeutics Inc fka NVLNF RSS Feed

Followers
12
Posters
80
Posts (Today)
0
Posts (Total)
765
Created
05/11/09
Type
Free
Moderators
http://www.qltinc.com/

http://finance.yahoo.com/q/ks?s=QLTI+Key+Statistics

QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle. The company was founded in 1981 and is headquartered in Vancouver, Canada.

Board Info
Posts Today
0
Posts (Total)
765
Posters
80
Moderators
New Post